Company intelligence / Profile preview

Innomab

California, United Statesinnomabinc.com ↗

Ownership: Private
Development stage: Other

Overview

Innomab is developing nimotuzumab, a humanized monoclonal antibody targeting EGFR. Nimotuzumab is marketed for several cancers in certain countries through various partners and is currently in Phase II clinical trials for pancreatic ductal adenocarcinoma under Innomab's sponsorship. The drug has orphan designation for some rare cancers and has been studied across multiple solid tumor indications with varying stages of development from preclinical to commercial.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBiologic (for nimotuzumab)
Industry: Biotech

Partnerships

Center of Molecular Immunology/CIMYM/various international licensees for nimotuzumab commercialization/development

Beyond the preview

Go deeper on Innomab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innomab.